Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

UBC researchers develop new way to target previously undruggable proteins

Researchers at the University of British Columbia and BC Cancer have developed a new way to target proteins long considered "undruggable," opening the door to new treatments for prostate cancer and other serious diseases.

28 Apr 2026

Repurposed cancer drugs offer potential breakthrough for Crohn’s disease treatment

University of Houston biologists have contributed to a potential breakthrough in treating Crohn's disease by shifting the clinical focus from symptom management to addressing a primary underlying cause of the condition.

27 Apr 2026

ISSCR urges NIH to continue support human embryonic stem cell research

The International Society for Stem Cell Research (ISSCR) has submitted a formal response to a Request for Information (RFI) issued by the National Institutes of Health (NIH) regarding its pause on new submissions to the NIH Human Embryonic Stem Cell (hESC) Registry and considerations to reduce reliance on hESCs in federally supported research.

25 Apr 2026

New computational protocol accelerates drug discovery for Chagas disease

Researchers at the University of Kent have established a computational protocol that could accelerate the development of more effective treatments for life-threatening parasitic infections such as Chagas disease, by enabling scientists to accurately identify reactions that can result in successful drug candidates without the need for trial and error.

25 Apr 2026

AI model rapidly designs new antibiotic to fight resistant bacteria

Researchers at McMaster University have developed a new generative artificial intelligence (AI) model capable of drastically speeding up drug discovery - and, in early tests, it has already designed a brand-new antibiotic.

23 Apr 2026

Researchers receive NIH grant to accelerate Alzheimer's drug discovery efforts

Dr. Damian Young, investigator at Texas Children's Duncan Neurological Research Institute (Duncan NRI) and director of the Center for Drug Discovery at Baylor College of Medicine, along with collaborators has been awarded a $6.7 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to develop new approaches to rapidly identify potential treatments for Alzheimer's disease and related dementias with the goal of accelerating the discovery of new therapies.

23 Apr 2026

Global experts highlight new strategies to target human aging

A new meeting report was published in Volume 18 of Aging-US on April 6, 2026, titled "Toward actionable interventions in human aging (12th ARDD meeting, 2025)."

22 Apr 2026

Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models

Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced the launch of STORganoid™, an ambient-temperature preservation solution for organoids and spheroids.

From Atelerix Ltd 21 Apr 2026

Proteomics and AI bring earlier risk prediction into sharper focus

This review examines how high-throughput proteomics is expanding precision medicine by improving biomarker discovery, disease prediction, and drug development. It also shows how AI is helping researchers interpret complex proteomic data while highlighting major barriers such as standardization, validation, and clinical translation.

19 Apr 2026

Stem cell model identifies promising therapy for inflammatory bowel disease

A new study published today in Stem Cell Reports demonstrates how a human stem cell-derived model of the intestine can be used to identify potential therapies for inflammatory bowel disease (IBD), highlighting glycyrrhizin as a promising candidate for reducing intestinal inflammation and cell death.

17 Apr 2026

Data management challenges in scientific research

Expert insights into CDD Vault's data management system explain how the platform uses the latest technology to support scientific workflows.

From Collaborative Drug Discovery, Inc. 17 Apr 2026

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery

ORGAPRED, a France-based core facility specializing in Patient-Derived Tumor Organoid (PDTO) research, has selected the CYTOQUBE high-throughput 3D imaging system from Hamamatsu Photonics France to support personalized oncology drug screening and therapeutic discovery.

From Hamamatsu Photonics Europe 15 Apr 2026

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity).

From Bio-Rad Laboratories 15 Apr 2026

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), appointing John Lambert as Chair, with Morris Rosenberg and Peter de Waele serving alongside.

From VALANX Biotech 15 Apr 2026